Women with ER positive metastatic breast cancer that is Bcl-2 positive and Her2 non-amplified may be eligible for inclusion in the m-BEP trial. Exposure to prior lines of endocrine therapy and chemotherapy is often acceptable, but cessation of anti-cancer therapy for 21 days prior to enrollment is essential.